Unique wound care OxyBand offers the first FDA-approved wound dressing that delivers pure oxygen for up to five days, presenting a compelling value proposition for healthcare providers seeking faster healing and reduced pain in wound care.

Clinical efficacy Multiple clinical trials show faster healing, lower pain, reduced exudate, and no infections compared to standard care, enabling sales conversations focused on measurable outcomes and potential cost savings.

Regulatory edge With FDA approval and a patented, bio-medical oxygen delivery platform, position OxyBand as a differentiated device in wound management cate gories, appealing to hospitals, burn centers, and military medical programs.

Strategic partnerships Target expansion into trauma, diabetic ulcers, orthopedics, and regenerative medicine markets through academic institutions and large health systems, leveraging existing trial data to support filings and procurement.

Market positioning Despite a small company size, align with leading medical device players and defense health programs by highlighting a strong patent portfolio, proven outcomes, and potential for broad adoption in acute and chronic wound care.